entertainment -WSS

entertainment

author：Wikipedia 2025-09-29 21:14:20 - browse：153

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.

Based on an interim analysis of a Phase 3 trial, the company said that the drug, datopotamab deruxtecan, led to improvement in progression-free survival in patients non-small cell lung cancer, a primary endpoint of the study. There was also a positive early trend on overall survival, with Susan Galbraith, AstraZeneca’s oncology leader, describing the results as “compelling evidence for the potential role” that the drug could play for patients.

But investors had been hoping for a clearer signal of benefit. Analysts noted that despite the success in progression-free survival, it was not described as a “clinically meaningful” improvement, which, as J.P. Morgan analysts wrote, “we believe the market would have liked to have seen.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： FTX founder Sam Bankman

hotspot

WSS

EU regulator recommends expanding Mounjaro approval to obesity

Independent physicians launch a new lobbying group

Humana cuts profit projections as Medicare Advantage costs soar

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

Readout Newsletter: Merck, J&J, and long Covid

The painfully weak evidence on taking collagen to treat arthritis

knowledge

entertainment

hotspot

Cancer drug shortages should be causing more outrage

The painfully weak evidence on taking collagen to treat arthritis

In age of alternative facts, a scholarly course on calling out crap

Francis Collins on trust in science and how Covid communications failed

Trump demands the U.S. pay no more for drugs than other countries … again

Parkinson’s finding may lead to tests and, someday, treatments

Heart attack and stroke risk calculators need revising

Mega Millions jackpot estimated at record $1.58 billion for Tuesday's drawing

Bright Health sells Medicare Advantage business to Molina

Travel bans should be based on evidence, not politics or fear

focus

Cheesesteak restaurant owner explains his secret sauce, the viral Malibu Barbie Dream Drizzle

Elizabeth Holmes banned from government health programs

Why doctors need education on FDA device approval process

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

How digital therapeutics firms are pivoting after Pear's bankruptcy

The painfully weak evidence on taking collagen to treat arthritis

hotspot

Wikipedia

knowledge

focus